Historical Context: Why 28.7% Matters
For decades, anti-obesity pharmacotherapy was limited to 5–10% body weight reduction. Semaglutide's 14.9% result (STEP 1, 2021) was called a breakthrough. Tirzepatide's 22.5% (SURMOUNT-1, 2022) was called unprecedented. Retatrutide's Phase 3 TRIUMPH-4 result — 28.7% at 68 weeks — eclipses every prior benchmark.
Bariatric surgery (gastric bypass) typically produces 25–30% total body weight loss over 1–2 years. Retatrutide is the first pharmacologic agent to approach surgical-level weight reduction in a randomized clinical trial.
Phase 3 Comparison: Mean Weight Loss by Compound
Phase 3 pivotal trial results. Sources: TRIUMPH-4, SURMOUNT-1, STEP 1, SCALE Obesity.
Phase 2 TRIUMPH-1 Results (NEJM, 2023)
Phase 2 TRIUMPH-1, published in the New England Journal of Medicine in 2023, enrolled adults with BMI ≥30 across five dose cohorts over 48 weeks. The 12mg group's 24.2% result was the highest Phase 2 result ever for an anti-obesity agent — surpassing all prior Phase 3 benchmarks with 24 fewer weeks of treatment.
| Dose (weekly) | Mean Weight Loss | ≥15% Responders | ≥20% Responders |
|---|---|---|---|
| Placebo | –2.1% | — | — |
| 1 mg | –8.7% | ~22% | ~9% |
| 4 mg | –17.3% | ~58% | ~38% |
| 8 mg | –22.8% | ~73% | ~55% |
| 12 mg | –24.2% | ~83% | ~65% |
Phase 3 TRIUMPH Data (2025–2026)
TRIUMPH-4 (December 2025)
TRIUMPH-4 is the landmark Phase 3 obesity trial. At 68 weeks, participants on 12mg Retatrutide achieved 28.7% mean body weight reduction — all primary and secondary endpoints met. Over 70% of participants achieved ≥20% weight loss; over 90% achieved ≥5%.
TRIUMPH-1 Phase 3 (May 2026)
The Phase 3 TRIUMPH-1 readout (distinct from Phase 2 TRIUMPH-1) confirmed the TRIUMPH-4 finding with 28.3% mean weight reduction at 68 weeks — providing the second large-scale Phase 3 dataset and satisfying FDA requirements for two adequate and well-controlled trials.
TRANSCEND-T2D-1 (March 2026)
In the type 2 diabetes population — historically harder to achieve high weight loss — Retatrutide met all primary HbA1c endpoints. Full weight loss data has not been published as of May 2026.
vs. Other Anti-Obesity Agents
| Compound | Mechanism | Phase 3 Weight Loss | Duration | Status |
|---|---|---|---|---|
| Retatrutide | GLP-1 + GIP + Glucagon | 28.7% | 68 wks | Phase 3 |
| Tirzepatide | GLP-1 + GIP | 22.5% | 72 wks | FDA Approved |
| Semaglutide | GLP-1 | 14.9% | 68 wks | FDA Approved |
| Liraglutide | GLP-1 | 6.0% | 56 wks | FDA Approved |
The ~6 percentage point gap between Retatrutide and Tirzepatide is attributed to glucagon receptor agonism — which drives thermogenesis and hepatic fat oxidation independently of appetite suppression. This is the mechanism that semaglutide and tirzepatide do not activate.
Secondary Endpoints
| Parameter | Direction | Significance |
|---|---|---|
| Waist circumference | ↓ Significant | Met |
| Hepatic fat fraction (MRI) | ↓ Pronounced | NASH data |
| HbA1c (T2D population) | ↓ Significant | Met — TRANSCEND |
| Fasting glucose | ↓ Significant | Met |
| LDL / triglycerides | ↓ Significant | Favorable |
| Systolic blood pressure | ↓ Moderate | Favorable |
| Visceral adipose tissue | ↓ Pronounced | Met |